Tonix Pharmaceuticals Holding Corp.
NASDAQ Capital MarketTotal Valuation
Tonix Pharmaceuticals Holding Corp. carries a market capitalization of 184.28M, placing it among publicly traded companies globally. Its enterprise value stands at -40.64M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 184.28M |
| Enterprise Value | -40.64M |
Share Statistics
Tonix Pharmaceuticals Holding Corp. currently has 14.21M shares outstanding.
| Shares Outstanding | 14.21M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 8.18, and the price-to-book ratio stands at -0.16.
| PE Ratio | N/A |
| PS Ratio | 8.18 |
| PB Ratio | -0.16 |
| P/TBV Ratio | 0.63 |
| P/FCF Ratio | -1.19 |
| P/OCF Ratio | -1.14 |
Enterprise Valuation
| EV / Sales | 16.88 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Tonix Pharmaceuticals Holding Corp. maintains a current ratio of 6.99, meaning it holds 7.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.99 |
| Quick Ratio | 6.68 |
| Debt / Equity | 0.57 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -65.39 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.14 |
Stock Price Statistics
Tonix Pharmaceuticals Holding Corp.'s stock has declined approximately -74.36807% over the past 52 weeks. The 50-day moving average sits at 12.46, while the 200-day moving average is 15.32.
| Beta (5Y) | N/A |
| 52-Week Price Change | -74.36807% |
| 50-Day Moving Average | 12.46 |
| 200-Day Moving Average | 15.32 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Tonix Pharmaceuticals Holding Corp. generated 17.56M in revenue and converted that into -147.39M in net income, yielding earnings per share of -14.12. EBITDA reached -147.11M, while operating income came in at -149.10M.
| Revenue | 17.56M |
| Gross Profit | 10.28M |
| Operating Income | -149.10M |
| Pretax Income | -147.39M |
| Net Income | -147.39M |
| EBITDA | -147.11M |
| EBIT | -149.10M |
| Earnings Per Share (EPS) | -14.12 |
Balance Sheet
Tonix Pharmaceuticals Holding Corp. holds 185.47M in cash and equivalents against 1.29M in total debt, resulting in a net debt position of -185.47M. Total book value stands at -894.89M, with working capital of 177.52M providing operational flexibility.
| Cash & Cash Equivalents | 185.47M |
| Total Debt | 1.29M |
| Net Debt | -185.47M |
| Equity (Book Value) | -894.89M |
| Book Value Per Share | -85.73 |
| Working Capital | 177.52M |
Cash Flow
Tonix Pharmaceuticals Holding Corp. produced -125.58M in operating cash flow over the past twelve months. After subtracting -5.05M in capital expenditures, free cash flow totaled -130.64M - equivalent to -12.51 per share.
| Operating Cash Flow | -125.58M |
| Capital Expenditures | -5.05M |
| Free Cash Flow | -130.64M |
| FCF Per Share | -12.51 |
Margins
Tonix Pharmaceuticals Holding Corp. operates with a gross margin of 58.56, reflecting its pricing power and cost economics. The operating margin of -849.27 and net profit margin of -839.52 provide insight into operational efficiency.
| Gross Margin | 58.56 |
| Operating Margin | -849.27 |
| Pretax Margin | -839.52 |
| Profit Margin | -839.52 |
| EBITDA Margin | -837.95 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -129.03 |
| FCF Yield | -83.97 |
Stock Splits
Tonix Pharmaceuticals Holding Corp.'s most recent stock split took place on February 5, 2025 with a 100:1 split ratio.
| Last Split Date | 2/5/2025 |
| Split Ratio | 100:1 |
Scores
Tonix Pharmaceuticals Holding Corp. posts an Altman Z-Score of -3.08, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.08 |